...
rckt-img

Rocket Pharmaceuticals Inc, Common Stock

RCKT

NMQ

$12.02

+$0.34

(2.91%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.24B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.93M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.09
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$11.15 L
$31.47 H
$12.02

About Rocket Pharmaceuticals Inc, Common Stock

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRCKTSectorS&P500
1-Week Return5.9%2.44%2.58%
1-Month Return-14.81%-4.49%0.09%
3-Month Return-31.7%-8.82%4.76%
6-Month Return-43.54%-4.46%9.89%
1-Year Return-61.46%3.16%26.47%
3-Year Return-47.28%-0.83%25.98%
5-Year Return-49.66%35.65%86.34%
10-Year Return-49.92%101.94%189.21%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue426.00K1.15M5.37M6.27M7.10M[{"date":"2019-12-31","value":6,"profit":true},{"date":"2020-12-31","value":16.13,"profit":true},{"date":"2021-12-31","value":75.7,"profit":true},{"date":"2022-12-31","value":88.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(426.00K)(1.15M)(5.37M)(6.27M)(7.10M)[{"date":"2019-12-31","value":-42600000,"profit":false},{"date":"2020-12-31","value":-114500000,"profit":false},{"date":"2021-12-31","value":-537300000,"profit":false},{"date":"2022-12-31","value":-626600000,"profit":false},{"date":"2023-12-31","value":-709800000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses75.90M134.30M166.25M223.84M259.66M[{"date":"2019-12-31","value":29.23,"profit":true},{"date":"2020-12-31","value":51.72,"profit":true},{"date":"2021-12-31","value":64.03,"profit":true},{"date":"2022-12-31","value":86.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(76.15M)(134.30M)(167.25M)(224.34M)(259.66M)[{"date":"2019-12-31","value":-7615100000,"profit":false},{"date":"2020-12-31","value":-13430300000,"profit":false},{"date":"2021-12-31","value":-16724800000,"profit":false},{"date":"2022-12-31","value":-22434300000,"profit":false},{"date":"2023-12-31","value":-25965900000,"profit":false}]
Total Non-Operating Income/Expense(3.66M)(10.21M)(4.64M)4.46M26.37M[{"date":"2019-12-31","value":-13.89,"profit":false},{"date":"2020-12-31","value":-38.74,"profit":false},{"date":"2021-12-31","value":-17.6,"profit":false},{"date":"2022-12-31","value":16.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(77.27M)(139.70M)(169.07M)(221.86M)(245.59M)[{"date":"2019-12-31","value":-7727000000,"profit":false},{"date":"2020-12-31","value":-13970000000,"profit":false},{"date":"2021-12-31","value":-16906900000,"profit":false},{"date":"2022-12-31","value":-22186300000,"profit":false},{"date":"2023-12-31","value":-24559500000,"profit":false}]
Income Taxes5.96M6.97M516.00K(2.48M)(245.59M)[{"date":"2019-12-31","value":85.52,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.41,"profit":true},{"date":"2022-12-31","value":-35.6,"profit":false},{"date":"2023-12-31","value":-3525.12,"profit":false}]
Income After Taxes(83.23M)(146.67M)(169.59M)(219.38M)-[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(77.52M)(139.70M)(169.07M)(221.86M)(252.66M)[{"date":"2019-12-31","value":-7752000000,"profit":false},{"date":"2020-12-31","value":-13970000000,"profit":false},{"date":"2021-12-31","value":-16906900000,"profit":false},{"date":"2022-12-31","value":-22186300000,"profit":false},{"date":"2023-12-31","value":-25265800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(83.23M)(146.67M)(169.59M)(219.38M)(245.59M)[{"date":"2019-12-31","value":-8322800000,"profit":false},{"date":"2020-12-31","value":-14666700000,"profit":false},{"date":"2021-12-31","value":-16958500000,"profit":false},{"date":"2022-12-31","value":-21938300000,"profit":false},{"date":"2023-12-31","value":-24559500000,"profit":false}]
EPS (Diluted)(1.58)(2.51)(2.68)(3.29)(2.94)[{"date":"2019-12-31","value":-158,"profit":false},{"date":"2020-12-31","value":-251,"profit":false},{"date":"2021-12-31","value":-268,"profit":false},{"date":"2022-12-31","value":-329,"profit":false},{"date":"2023-12-31","value":-294,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RCKT
Cash Ratio 5.89
Current Ratio 6.05

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RCKT
ROA (LTM) -34.48%
ROE (LTM) -59.27%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RCKT
Debt Ratio Lower is generally better. Negative is bad. 0.16
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.84

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RCKT
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 3.77
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Rocket Pharmaceuticals Inc share price today?

Rocket Pharmaceuticals Inc (RCKT) share price today is $12.02

Can Indians buy Rocket Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Rocket Pharmaceuticals Inc (RCKT) on Vested. To buy Rocket Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RCKT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Rocket Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Rocket Pharmaceuticals Inc (RCKT) via the Vested app. You can start investing in Rocket Pharmaceuticals Inc (RCKT) with a minimum investment of $1.

How to invest in Rocket Pharmaceuticals Inc shares from India?

You can invest in shares of Rocket Pharmaceuticals Inc (RCKT) via Vested in three simple steps:

  • Click on Sign Up or Invest in RCKT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Rocket Pharmaceuticals Inc shares
What is Rocket Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Rocket Pharmaceuticals Inc (RCKT) is $31.47. The 52-week low price of Rocket Pharmaceuticals Inc (RCKT) is $11.15.

What is Rocket Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Rocket Pharmaceuticals Inc (RCKT) is

What is Rocket Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Rocket Pharmaceuticals Inc (RCKT) is 3.77

What is Rocket Pharmaceuticals Inc dividend yield?

The dividend yield of Rocket Pharmaceuticals Inc (RCKT) is 0.00%

What is the Market Cap of Rocket Pharmaceuticals Inc?

The market capitalization of Rocket Pharmaceuticals Inc (RCKT) is $1.24B

What is Rocket Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Rocket Pharmaceuticals Inc is RCKT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top